- Home
- IKT vs CIGL Comparison
IKT vs CIGL Comparison
Compare IKT & CIGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IKT
- CIGL
- Stock Information
- Founded
- IKT 2008
- CIGL 1997
- Country
- IKT United States
- CIGL Singapore
- Employees
- IKT N/A
- CIGL N/A
- Industry
- IKT Biotechnology: Pharmaceutical Preparations
- CIGL Diversified Commercial Services
- Sector
- IKT Health Care
- CIGL Consumer Discretionary
- Exchange
- IKT Nasdaq
- CIGL Nasdaq
- Market Cap
- IKT 131.6M
- CIGL 145.9M
- IPO Year
- IKT 2020
- CIGL 2025
- Fundamental
- Price
- IKT $1.66
- CIGL $6.59
- Analyst Decision
- IKT Buy
- CIGL
- Analyst Count
- IKT 2
- CIGL 0
- Target Price
- IKT $8.00
- CIGL N/A
- AVG Volume (30 Days)
- IKT 126.7K
- CIGL 16.5K
- Earning Date
- IKT 08-13-2025
- CIGL 01-01-0001
- Dividend Yield
- IKT N/A
- CIGL N/A
- EPS Growth
- IKT N/A
- CIGL N/A
- EPS
- IKT N/A
- CIGL N/A
- Revenue
- IKT N/A
- CIGL $10,490,668.00
- Revenue This Year
- IKT N/A
- CIGL N/A
- Revenue Next Year
- IKT N/A
- CIGL N/A
- P/E Ratio
- IKT N/A
- CIGL N/A
- Revenue Growth
- IKT N/A
- CIGL N/A
- 52 Week Low
- IKT $1.12
- CIGL $3.63
- 52 Week High
- IKT $4.20
- CIGL $7.80
- Technical
- Relative Strength Index (RSI)
- IKT 35.43
- CIGL N/A
- Support Level
- IKT $1.91
- CIGL N/A
- Resistance Level
- IKT $2.07
- CIGL N/A
- Average True Range (ATR)
- IKT 0.11
- CIGL 0.00
- MACD
- IKT -0.03
- CIGL 0.00
- Stochastic Oscillator
- IKT 0.00
- CIGL 0.00
About IKT Inhibikase Therapeutics Inc.
Inhibikase Therapeutics Inc is a a clinical-stage pharmaceutical company developing protein kinase inhibitor therapeutics to modify the course of Parkinson's disease (PD), Parkinson's-related disorders and other diseases of the Abelson Tyrosine Kinases. Its multi-therapeutic pipeline has a primary focus on neurodegeneration and its program utilizing Risvodetinib (also known as IkT-148009), a selective inhibitor of the non-receptor Abelson Tyrosine Kinases, targets the treatment of Parkinson's disease inside and outside the brain as well as other diseases that arise from Abelson Tyrosine Kinases.
About CIGL Concorde International Group Ltd Class A Ordinary Shares
Concorde International Group Ltd is an integrated security services provider that combines physical manpower and technology to deliver effective security solutions. The company offers a range of services to enhance security and safety: (1) i-Guarding Services; (2) Man-Guarding Services; and (3) Consultancy and Training Services. Its i-Guarding Services leverages technology to increase efficiency, with a mobile platform and cluster aggregation model of a higher skillset workforce. It has two operating segments, which are (i) security services; and (ii) training school. Key revenue is generated from Security Services.